ZA200007653B - Characterisation of gene function using double stranded RNA inhibition. - Google Patents
Characterisation of gene function using double stranded RNA inhibition. Download PDFInfo
- Publication number
- ZA200007653B ZA200007653B ZA200007653A ZA200007653A ZA200007653B ZA 200007653 B ZA200007653 B ZA 200007653B ZA 200007653 A ZA200007653 A ZA 200007653A ZA 200007653 A ZA200007653 A ZA 200007653A ZA 200007653 B ZA200007653 B ZA 200007653B
- Authority
- ZA
- South Africa
- Prior art keywords
- dna
- promoter
- transcription factor
- organism
- vector
- Prior art date
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title claims description 120
- 108090000623 proteins and genes Proteins 0.000 title claims description 115
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title claims description 78
- 230000005764 inhibitory process Effects 0.000 title description 8
- 238000012512 characterization method Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims description 129
- 239000013598 vector Substances 0.000 claims description 128
- 108020004414 DNA Proteins 0.000 claims description 117
- 108091023040 Transcription factor Proteins 0.000 claims description 75
- 102000040945 Transcription factor Human genes 0.000 claims description 75
- 239000012634 fragment Substances 0.000 claims description 67
- 210000004027 cell Anatomy 0.000 claims description 63
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 60
- 230000014509 gene expression Effects 0.000 claims description 52
- 239000013612 plasmid Substances 0.000 claims description 52
- 239000002773 nucleotide Substances 0.000 claims description 49
- 125000003729 nucleotide group Chemical group 0.000 claims description 48
- 239000002299 complementary DNA Substances 0.000 claims description 43
- 238000013518 transcription Methods 0.000 claims description 43
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 42
- 230000035897 transcription Effects 0.000 claims description 42
- 230000009261 transgenic effect Effects 0.000 claims description 41
- 241000588724 Escherichia coli Species 0.000 claims description 37
- 238000010367 cloning Methods 0.000 claims description 24
- 241000244206 Nematoda Species 0.000 claims description 22
- 238000002474 experimental method Methods 0.000 claims description 21
- 230000000977 initiatory effect Effects 0.000 claims description 20
- 210000001519 tissue Anatomy 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 18
- 239000003550 marker Substances 0.000 claims description 18
- 238000001086 yeast two-hybrid system Methods 0.000 claims description 18
- 230000010354 integration Effects 0.000 claims description 15
- 230000001939 inductive effect Effects 0.000 claims description 14
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 13
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 13
- 230000000692 anti-sense effect Effects 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 244000005700 microbiome Species 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 11
- 230000033228 biological regulation Effects 0.000 claims description 10
- 241000607479 Yersinia pestis Species 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 101000936911 Chionoecetes opilio Sarcoplasmic/endoplasmic reticulum calcium ATPase Proteins 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 230000006801 homologous recombination Effects 0.000 claims description 7
- 238000002744 homologous recombination Methods 0.000 claims description 7
- 101150015886 nuc-1 gene Proteins 0.000 claims description 7
- 230000001131 transforming effect Effects 0.000 claims description 7
- 108700019146 Transgenes Proteins 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 101150110777 let-858 gene Proteins 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 230000009466 transformation Effects 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 6
- 101100459320 Caenorhabditis elegans myo-2 gene Proteins 0.000 claims description 5
- 108020004705 Codon Proteins 0.000 claims description 5
- 108700008625 Reporter Genes Proteins 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 230000004083 survival effect Effects 0.000 claims description 5
- 206010061217 Infestation Diseases 0.000 claims description 4
- 101150117157 MYO3 gene Proteins 0.000 claims description 4
- 108060001084 Luciferase Proteins 0.000 claims description 3
- 239000005089 Luciferase Substances 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 238000010396 two-hybrid screening Methods 0.000 claims description 3
- 241000380490 Anguina Species 0.000 claims description 2
- 241000294569 Aphelenchoides Species 0.000 claims description 2
- 241000580217 Belonolaimus Species 0.000 claims description 2
- 241000243770 Bursaphelenchus Species 0.000 claims description 2
- 241000244203 Caenorhabditis elegans Species 0.000 claims description 2
- 241000399934 Ditylenchus Species 0.000 claims description 2
- 102000002464 Galactosidases Human genes 0.000 claims description 2
- 108010093031 Galactosidases Proteins 0.000 claims description 2
- 241001442498 Globodera Species 0.000 claims description 2
- 241001480224 Heterodera Species 0.000 claims description 2
- 241001540513 Hoplolaimus Species 0.000 claims description 2
- 241001220360 Longidorus Species 0.000 claims description 2
- 241001143352 Meloidogyne Species 0.000 claims description 2
- 241000201433 Nacobbus Species 0.000 claims description 2
- 241001220391 Paratrichodorus Species 0.000 claims description 2
- 241000193943 Pratylenchus Species 0.000 claims description 2
- 241000201377 Radopholus Species 0.000 claims description 2
- 241001540480 Rotylenchulus Species 0.000 claims description 2
- 241001220308 Trichodorus Species 0.000 claims description 2
- 241001267618 Tylenchulus Species 0.000 claims description 2
- 101150033660 UL6 gene Proteins 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 108010065868 RNA polymerase SP6 Proteins 0.000 claims 2
- 210000001161 mammalian embryo Anatomy 0.000 claims 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 claims 1
- 239000005090 green fluorescent protein Substances 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 description 24
- 230000009368 gene silencing by RNA Effects 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 22
- 241000894006 Bacteria Species 0.000 description 17
- 230000006870 function Effects 0.000 description 14
- 238000010276 construction Methods 0.000 description 13
- 210000003205 muscle Anatomy 0.000 description 13
- 238000011176 pooling Methods 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 5
- 210000003800 pharynx Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000003071 parasitic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 101100528916 Caenorhabditis elegans rol-6 gene Proteins 0.000 description 3
- 101100048437 Caenorhabditis elegans unc-22 gene Proteins 0.000 description 3
- 101100243717 Cochliobolus carbonum PGN1 gene Proteins 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 101150066002 GFP gene Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 101100016388 Arabidopsis thaliana PAS2 gene Proteins 0.000 description 2
- 101100011366 Caenorhabditis elegans egl-15 gene Proteins 0.000 description 2
- 101100071585 Caenorhabditis elegans hsp-16.2 gene Proteins 0.000 description 2
- 101100074836 Caenorhabditis elegans lin-22 gene Proteins 0.000 description 2
- 101100353517 Caenorhabditis elegans pas-2 gene Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 101100297150 Komagataella pastoris PEX3 gene Proteins 0.000 description 2
- 101710128836 Large T antigen Proteins 0.000 description 2
- 206010028347 Muscle twitching Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101100315760 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PEX4 gene Proteins 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 101150086731 ges-1 gene Proteins 0.000 description 2
- 230000010196 hermaphroditism Effects 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 101150114748 unc-119 gene Proteins 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 101150029062 15 gene Proteins 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 101100064098 Caenorhabditis elegans dpy-7 gene Proteins 0.000 description 1
- 101100347613 Caenorhabditis elegans unc-54 gene Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 101150046414 ce gene Proteins 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 101150034492 gdhA-2 gene Proteins 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000010379 pull-down assay Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
- C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
- C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
- C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
- C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
- C12N15/8285—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for nematode resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10211—Podoviridae
- C12N2795/10241—Use of virus, viral particle or viral elements as a vector
- C12N2795/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
- Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Catching Or Destruction (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9814536.0A GB9814536D0 (en) | 1998-07-03 | 1998-07-03 | Characterisation of gene function using double stranded rna inhibition |
GBGB9827152.1A GB9827152D0 (en) | 1998-07-03 | 1998-12-09 | Characterisation of gene function using double stranded rna inhibition |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200007653B true ZA200007653B (en) | 2002-09-19 |
Family
ID=26313977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200007653A ZA200007653B (en) | 1998-07-03 | 2000-12-19 | Characterisation of gene function using double stranded RNA inhibition. |
Country Status (28)
Country | Link |
---|---|
US (3) | US20030061626A1 (es) |
EP (5) | EP1197567B2 (es) |
JP (3) | JP4353639B2 (es) |
KR (4) | KR20040066200A (es) |
CN (3) | CN1198938C (es) |
AT (2) | ATE433500T1 (es) |
AU (1) | AU769223B2 (es) |
BR (1) | BR9911802A (es) |
CA (2) | CA2332619C (es) |
CY (2) | CY1108920T1 (es) |
CZ (2) | CZ303494B6 (es) |
DE (5) | DE29924299U1 (es) |
DK (2) | DK1197567T4 (es) |
ES (2) | ES2327334T3 (es) |
GB (4) | GB9827152D0 (es) |
HK (1) | HK1029142A1 (es) |
HU (1) | HU230602B1 (es) |
IL (3) | IL140467A0 (es) |
IN (2) | IN2001DE00006A (es) |
IS (1) | IS2816B (es) |
MX (1) | MX234065B (es) |
NO (1) | NO327729B1 (es) |
NZ (1) | NZ509182A (es) |
PL (3) | PL213379B1 (es) |
PT (2) | PT1484415E (es) |
RU (1) | RU2240349C2 (es) |
WO (1) | WO2000001846A2 (es) |
ZA (1) | ZA200007653B (es) |
Families Citing this family (257)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
CN101818145A (zh) * | 1998-03-20 | 2010-09-01 | 联邦科学和工业研究组织 | 控制基因表达 |
GB9827152D0 (en) * | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
WO2000044914A1 (en) * | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
US7601494B2 (en) | 1999-03-17 | 2009-10-13 | The University Of North Carolina At Chapel Hill | Method of screening candidate compounds for susceptibility to biliary excretion |
BR0009884A (pt) * | 1999-04-21 | 2002-01-08 | American Home Prod | Processos e composições para a inibição da função das sequências de polinucleotìdeos |
US20040138168A1 (en) * | 1999-04-21 | 2004-07-15 | Wyeth | Methods and compositions for inhibiting the function of polynucleotide sequences |
US6924109B2 (en) * | 1999-07-30 | 2005-08-02 | Agy Therapeutics, Inc. | High-throughput transcriptome and functional validation analysis |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
GB9927444D0 (en) * | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
GB9930691D0 (en) * | 1999-12-24 | 2000-02-16 | Devgen Nv | Improvements relating to double-stranded RNA inhibition |
US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US8202846B2 (en) | 2000-03-16 | 2012-06-19 | Cold Spring Harbor Laboratory | Methods and compositions for RNA interference |
JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Rna干渉の方法とrna干渉組成物 |
EP2028278B1 (en) | 2000-03-30 | 2014-03-19 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
GB0012229D0 (en) | 2000-05-19 | 2000-07-12 | Devgen Nv | Lipid uptake assays |
GB0012233D0 (en) | 2000-05-19 | 2000-07-12 | Devgen Nv | Vector constructs |
GB2362383B (en) * | 2000-05-19 | 2003-12-31 | Devgen Nv | Gene expression system |
US7083947B2 (en) | 2000-05-19 | 2006-08-01 | Devgen Nv | Assay techniques using nematode worms |
AU2001275474A1 (en) * | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
US20030190635A1 (en) * | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
ATE373724T2 (de) | 2000-12-01 | 2007-10-15 | Max Planck Gesellschaft | Kleine rns moleküle, die rns-interferenz vermitteln |
US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
IL157087A0 (en) * | 2001-01-25 | 2004-02-08 | Virxsys Corp | A method for identifying a function of a gene sequence |
EP1354035B1 (en) | 2001-01-26 | 2016-08-24 | Commonwealth Scientific and Industrial Research Organisation | Methods and means for producing efficient silencing construct using recombinational cloning |
US20020132257A1 (en) | 2001-01-31 | 2002-09-19 | Tony Giordano | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
WO2002063037A2 (en) * | 2001-02-02 | 2002-08-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for identifying functional nucleic acids |
WO2003070972A2 (en) * | 2002-02-20 | 2003-08-28 | Sirna Therapeutics Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US7517864B2 (en) | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
EP3231445A1 (en) | 2001-05-18 | 2017-10-18 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
WO2003070884A2 (en) * | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2003006477A1 (en) | 2001-07-12 | 2003-01-23 | University Of Massachusetts | IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
US7612194B2 (en) * | 2001-07-24 | 2009-11-03 | Monsanto Technology Llc | Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof |
EP1431392B1 (en) * | 2001-08-31 | 2010-04-21 | Riken | PLANT SYSTEM FOR COMPREHENSIVE GENE FUNCTION ANALYSIS WITH THE USE OF FULL-LENGTH cDNA |
US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
US20030150017A1 (en) * | 2001-11-07 | 2003-08-07 | Mesa Jose Ramon Botella | Method for facilitating pathogen resistance |
DE10202419A1 (de) | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
ATE529512T1 (de) | 2002-02-01 | 2011-11-15 | Life Technologies Corp | Doppelsträngige oligonukleotide |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
EP1572902B1 (en) * | 2002-02-01 | 2014-06-11 | Life Technologies Corporation | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE |
EP1472265A4 (en) * | 2002-02-20 | 2005-06-15 | Sirna Therapeutics Inc | RNA INTERFERENCE MEDIA INHIBITION OF THE EXPRESSION OF THE POLYCOMB GROUP EZH2 PROTEIN GENE USING A SHORT INTERFERING NUCLEIC ACID (SINA) |
AU2003211058A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US7667029B2 (en) | 2002-02-20 | 2010-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
AU2003213057A1 (en) * | 2002-02-20 | 2003-09-09 | Ribozyme Pharmaceuticals, Incoporated | Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid |
AU2003228667A1 (en) * | 2002-04-22 | 2003-12-19 | Sirna Therapeutics Inc. | Nucleic acid mediated disruption of hiv fusogenic peptide interactions |
US20040180438A1 (en) | 2002-04-26 | 2004-09-16 | Pachuk Catherine J. | Methods and compositions for silencing genes without inducing toxicity |
AU2003239851A1 (en) * | 2002-05-08 | 2003-11-11 | Xantos Biomedicine Ag | Expression constructs for producing double-stranded (ds) rna and the use thereof |
AU2003239706A1 (en) * | 2002-05-23 | 2003-12-12 | Devgen Nv | Method for determining the influence of a compound on cholesterol transport |
JP2005529624A (ja) * | 2002-06-21 | 2005-10-06 | シノゲノマックス カンパニー リミテッド | ランダムdnaライブラリーと二本鎖rnaライブラリー、その用途および生産方法 |
US7803984B2 (en) * | 2002-07-10 | 2010-09-28 | Kansas State University Research Foundation | Compositions and methods for controlling plant parasitic nematodes |
US7655790B2 (en) | 2002-07-12 | 2010-02-02 | Sirna Therapeutics, Inc. | Deprotection and purification of oligonucleotides and their derivatives |
DK3222724T3 (en) | 2002-08-05 | 2018-12-03 | Silence Therapeutics Gmbh | ADDITIONALLY UNKNOWN FORMS OF INTERFERRING RNA MOLECULES |
AU2003261449A1 (en) | 2002-08-07 | 2004-02-25 | Compositions for rna interference and methods of use thereof | |
AU2003264727A1 (en) * | 2002-09-04 | 2004-03-29 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Compositions and methods for tissue specific or inducible inhibition of gene expression |
US7956176B2 (en) | 2002-09-05 | 2011-06-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
JP4786904B2 (ja) | 2002-11-27 | 2011-10-05 | セクエノム,インコーポレイティド | 配列変化検出及び発見用の断片化をベースとする方法及びシステム |
WO2004056982A2 (en) * | 2002-12-23 | 2004-07-08 | Devgen Nv | Kinase sequences |
EP3222294A1 (en) | 2003-04-30 | 2017-09-27 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
IL155783A (en) | 2003-05-05 | 2010-11-30 | Technion Res & Dev Foundation | Multicellular systems of multi-potential embryonic human stem cells and cancer cells and their use |
DK1633784T3 (da) | 2003-05-09 | 2011-10-24 | Diadexus Inc | OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder |
EP1644494A2 (en) * | 2003-06-17 | 2006-04-12 | Devgen NV | Alcohol dehydrogenase sequences useful for developing compounds for the prevention and/or treatment of metabolic diseases |
US9394565B2 (en) | 2003-09-05 | 2016-07-19 | Agena Bioscience, Inc. | Allele-specific sequence variation analysis |
WO2005049841A1 (en) * | 2003-11-17 | 2005-06-02 | Commonwealth Scientific And Industrial Research Organisation | Insect resistance using inhibition of gene expression |
JP4682152B2 (ja) | 2003-12-31 | 2011-05-11 | ザ・ペン・ステート・リサーチ・ファンデーション | 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 |
EP1713915B1 (en) | 2004-02-10 | 2009-12-16 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (MULTIFUNCTIONAL siNA) |
US20060019914A1 (en) | 2004-02-11 | 2006-01-26 | University Of Tennessee Research Foundation | Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes |
US7622301B2 (en) * | 2004-02-24 | 2009-11-24 | Basf Plant Science Gmbh | Compositions and methods using RNA interference for control of nematodes |
US9249456B2 (en) | 2004-03-26 | 2016-02-02 | Agena Bioscience, Inc. | Base specific cleavage of methylation-specific amplification products in combination with mass analysis |
US7608394B2 (en) * | 2004-03-26 | 2009-10-27 | Sequenom, Inc. | Methods and compositions for phenotype identification based on nucleic acid methylation |
CN1964740A (zh) | 2004-04-02 | 2007-05-16 | 加利福尼亚大学董事会 | 治疗和预防与αVβ5整联蛋白有关的疾病的方法和组合物 |
EP1732379B1 (en) | 2004-04-09 | 2013-11-06 | Monsanto Technology LLC | Compositions and methods for control of insect infestations in plants |
WO2005105157A2 (en) | 2004-04-23 | 2005-11-10 | The Trustees Of Columbia University In The City Ofnew York | INHIBITION OF HAIRLESS PROTEIN mRNA |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
ATE501252T1 (de) | 2004-06-22 | 2011-03-15 | Univ Illinois | Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns |
US7968762B2 (en) | 2004-07-13 | 2011-06-28 | Van Andel Research Institute | Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF) |
CA2579574A1 (en) | 2004-07-23 | 2007-01-04 | The University Of North Carolina At Chapel Hill | Methods and materials for determining pain sensitivity and predicting and treating related disorders |
WO2006017932A1 (en) | 2004-08-18 | 2006-02-23 | Genesense Technologies Inc. | Small interfering rna molecules against ribonucleotide reductase and uses thereof |
ES2534426T3 (es) | 2004-09-24 | 2015-04-22 | J.R. Simplot Company | Silenciamiento génico |
US20060247197A1 (en) | 2004-10-04 | 2006-11-02 | Van De Craen Marc | Method for down-regulating gene expression in fungi |
KR20070093962A (ko) | 2004-10-13 | 2007-09-19 | 유니버시티 오브 죠지아 리서치 파운데이션, 인코포레이티드 | 선충류에 저항하는 유전자 도입 식물들 |
AU2005299492B2 (en) | 2004-10-21 | 2011-09-01 | Venganza, Inc. | Methods and materials for conferring resistance to pests and pathogens of plants |
EP1807520B1 (en) | 2004-10-25 | 2012-07-25 | Devgen NV | Rna constructs |
WO2006045591A2 (en) * | 2004-10-25 | 2006-05-04 | Devgen N.V. | Method and constructs for delivering double stranded rna to pest organisms |
EP2230517A1 (en) | 2005-01-07 | 2010-09-22 | Diadexus, Inc. | OVR110 antibody compositions and methods of use |
US8088976B2 (en) * | 2005-02-24 | 2012-01-03 | Monsanto Technology Llc | Methods for genetic control of plant pest infestation and compositions thereof |
DE202005004135U1 (de) * | 2005-03-11 | 2005-05-19 | Klocke Verpackungs-Service Gmbh | Mehrkomponentenverpackung mit Applikator |
AU2006230436B2 (en) | 2005-03-31 | 2011-11-24 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
WO2006124699A2 (en) | 2005-05-12 | 2006-11-23 | Wisconsin Alumni Research Foundation | Blockade of pin1 prevents cytokine production by activated immune cells |
JP5832062B2 (ja) | 2005-05-31 | 2015-12-16 | デフヘン・ナムローゼ・フェンノートシャップDEVGEN nv | 昆虫及びクモの防除のためのRNAi |
US8703769B2 (en) | 2005-07-15 | 2014-04-22 | The University Of North Carolina At Chapel Hill | Use of EGFR inhibitors to prevent or treat obesity |
EP2275562B1 (en) | 2005-09-16 | 2015-10-21 | deVGen N.V. | Transgenic plant-based methods for plant insect pests using RNAi |
AP2008004416A0 (en) | 2005-09-16 | 2008-04-30 | Monsanto Technology Llc | Methods for genetic control of insect infestationsin plants and compositions thereof |
BRPI0615792A2 (pt) | 2005-09-16 | 2009-06-16 | Devgen Nv | métodos de controle de pestes com base no uso de rnai |
EP1931789B1 (en) | 2005-09-20 | 2016-05-04 | BASF Plant Science GmbH | Methods for controlling gene expression using ta-siran |
US9286469B2 (en) * | 2005-12-16 | 2016-03-15 | Cisco Technology, Inc. | Methods and apparatus providing computer and network security utilizing probabilistic signature generation |
EP1974041A2 (en) | 2006-01-06 | 2008-10-01 | University Of Georgia Research Foundation, Inc. | Cyst nematode resistant transgenic plants |
US8906876B2 (en) | 2006-01-12 | 2014-12-09 | Devgen Nv | Methods for controlling pests using RNAi |
US20090298787A1 (en) | 2006-01-12 | 2009-12-03 | Devgen N.V. | Dsrna as Insect Control Agent |
BRPI0706266A2 (pt) | 2006-01-12 | 2009-02-25 | Devgen Nv | mÉtodos para controle de pragas usando a rnai |
US20080022423A1 (en) * | 2006-02-03 | 2008-01-24 | Monsanto Technology Llc | IN PLANTA RNAi CONTROL OF FUNGI |
CA2637665A1 (en) | 2006-02-10 | 2007-08-23 | Monsanto Technology Llc | Identification and use of target genes for control of the plant parasitic nematodes heterodera glycines |
US20070259785A1 (en) * | 2006-02-13 | 2007-11-08 | Monsanto Technology Llc | SELECTING AND STABILIZING dsRNA CONSTRUCTS |
US20100068172A1 (en) * | 2006-03-16 | 2010-03-18 | Devgen N.V. | Nematode Control |
WO2007123777A2 (en) | 2006-03-30 | 2007-11-01 | Duke University | Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses |
PL216037B1 (pl) * | 2006-06-09 | 2014-02-28 | Inst Biotechnologii I Antybiotykow | Kaseta ekspresyjna, zastosowanie kasety ekspresyjnej, wektor, komórka gospodarza oraz sposób otrzymywania polipeptydu |
CN101511181B (zh) | 2006-07-11 | 2013-08-21 | 新泽西医科和牙科大学 | 蛋白、编码该蛋白的核酸和相关的应用方法 |
EP2412383A1 (en) | 2006-07-28 | 2012-02-01 | Children's Memorial Hospital | Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells |
AU2007325283B2 (en) | 2006-11-27 | 2012-08-30 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
CN101195821A (zh) * | 2006-12-04 | 2008-06-11 | 中国科学院上海生命科学研究院 | 利用RNAi技术改良植物抗虫性的方法 |
US20100129358A1 (en) | 2006-12-22 | 2010-05-27 | University Of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
WO2008092153A2 (en) | 2007-01-26 | 2008-07-31 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
US20080184391A1 (en) * | 2007-01-29 | 2008-07-31 | Kuppuswamy Subramaniam | Pathogen resistant transgenic plants, associated nucleic acids and techniques involving the same |
US8410334B2 (en) | 2007-02-20 | 2013-04-02 | Monsanto Technology Llc | Invertebrate microRNAs |
HUE027018T2 (en) | 2007-03-21 | 2016-08-29 | Brookhaven Science Ass Llc | Combination hairpin antisense compositions and methods for modulating expression |
EP2377952A1 (en) | 2007-04-26 | 2011-10-19 | Ludwig Institute For Cancer Research | Methods for diagnosing and treating astrocytomas |
EP2607477B1 (en) | 2007-05-03 | 2020-09-23 | The Brigham and Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
US8097422B2 (en) | 2007-06-20 | 2012-01-17 | Salk Institute For Biological Studies | Kir channel modulators |
WO2009006450A1 (en) * | 2007-06-29 | 2009-01-08 | Boston Biomedical, Inc. | Bacteria-mediated gene modulation via microrna machinery |
US9689031B2 (en) | 2007-07-14 | 2017-06-27 | Ionian Technologies, Inc. | Nicking and extension amplification reaction for the exponential amplification of nucleic acids |
WO2009012263A2 (en) | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
US20110131668A1 (en) | 2007-08-14 | 2011-06-02 | Commonwealth Scientific And Industrial Research Organisation | Improved gene silencing methods |
KR101142209B1 (ko) | 2007-09-22 | 2012-05-04 | 재단법인서울대학교산학협력재단 | 섭취 RNAi를 이용한 꼬마선충에서 두 유전자의동시발현 억제방법 |
US7968525B1 (en) | 2007-12-03 | 2011-06-28 | University Of Florida Research Foundation, Inc. | Use of RNA interference to validate new termiticide target sites and a method of termite control |
AU2009232355A1 (en) | 2008-04-04 | 2009-10-08 | Calando Pharmaceuticals, Inc. | Compositions and use of EPAS1 inhibitors |
CN107267514A (zh) | 2008-04-10 | 2017-10-20 | 孟山都技术公司 | 用于根结线虫防治的方法和组合物 |
GB0807018D0 (en) | 2008-04-17 | 2008-05-21 | Fusion Antibodies Ltd | Antibodies and treatment |
WO2010054221A2 (en) | 2008-11-06 | 2010-05-14 | The Johns Hopkins University | Treatment of chronic inflammatory respiratory disorders |
EP2687609B1 (en) | 2008-11-10 | 2017-01-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Method for treating solid tumor |
EP2379722B1 (de) | 2008-12-16 | 2016-09-07 | c-LEcta GmbH | Expressionsvektor |
JP2012513464A (ja) | 2008-12-23 | 2012-06-14 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | ホスホジエステラーゼ阻害剤及びその使用 |
WO2010074783A1 (en) | 2008-12-23 | 2010-07-01 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
WO2010107958A1 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120029054A1 (en) | 2009-03-19 | 2012-02-02 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA) |
EP2408916A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
MX2011009724A (es) | 2009-03-19 | 2011-10-14 | Merck Sharp & Dohme | Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen del factor de transcripcion basico de cierre de leucina 1 de homologia de btb y cnc 1, usando el listado de secuencias de acido nucleico corto de interferencia. |
SG174581A1 (en) | 2009-03-27 | 2011-10-28 | Merck Sharp & Dohme | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
US20120022142A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
WO2010111490A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120010272A1 (en) | 2009-03-27 | 2012-01-12 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20100257634A1 (en) * | 2009-04-03 | 2010-10-07 | Venganza Inc. | Bioassay for gene silencing constructs |
US8283332B2 (en) | 2009-04-17 | 2012-10-09 | University Of Louisville Research Foundation, Inc. | PFKFB4 inhibitors and methods of using the same |
EP2258858A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Transgenic LSD1 animal model for cancer |
WO2011008823A2 (en) | 2009-07-14 | 2011-01-20 | Mayo Foundation For Medical Education And Research | Peptide-mediated non-covalent delivery of active agents across the blood brain barrier |
CA2767409C (en) | 2009-07-24 | 2018-10-30 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin |
CA3067381C (en) * | 2009-08-28 | 2023-02-07 | E. I. Du Pont De Nemours And Company | Compositions and methods to control insect pests |
US9163240B2 (en) | 2009-12-07 | 2015-10-20 | The Johns Hopkins University | SR-BI mutation as a predictor of low progesterone levels and poor fetal viability during pregnancy |
TWI611021B (zh) | 2009-12-09 | 2018-01-11 | 日東電工股份有限公司 | Hsp47表現之調節 |
US10640457B2 (en) | 2009-12-10 | 2020-05-05 | The Trustees Of Columbia University In The City Of New York | Histone acetyltransferase activators and uses thereof |
EP3632901B1 (en) | 2009-12-10 | 2022-02-02 | The Trustees of Columbia University in the City of New York | Histone acetyltransferase activators and uses thereof |
EP2513309A2 (en) | 2009-12-18 | 2012-10-24 | Novartis AG | Organic compositions to treat hsf1-related diseases |
EA026374B1 (ru) | 2009-12-23 | 2017-04-28 | Новартис Аг | Липиды, липидные композиции и способы их применения |
HUE033044T2 (hu) | 2010-01-26 | 2017-11-28 | Nat Jewish Health | Eljárás tüdõ rendellenességek kockázatának elõrejelzésére, diagnózisára, kórjóslatára |
CN102770767A (zh) | 2010-02-10 | 2012-11-07 | 诺瓦提斯公司 | 用于肌肉生长的方法和组合物 |
US9273316B2 (en) | 2010-05-21 | 2016-03-01 | Peptimed, Inc. | Reagents and methods for treating cancer |
GB201009601D0 (en) | 2010-06-08 | 2010-07-21 | Devgen Private Ltd | Method for down-grading gene expression in fungi |
WO2011163466A1 (en) | 2010-06-23 | 2011-12-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulation of skin pigmentation by neuregulin-1 (nrg-1) |
EP3330377A1 (en) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
CN108676800B (zh) | 2010-08-17 | 2022-11-11 | 瑟纳治疗公司 | 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制 |
EP2609198B8 (en) | 2010-08-24 | 2018-03-28 | Sirna Therapeutics, Inc. | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER |
WO2012027467A1 (en) | 2010-08-26 | 2012-03-01 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20140134231A1 (en) | 2010-10-11 | 2014-05-15 | Sanford-Burnham Medical Research Institute | Mir-211 expression and related pathways in human melanoma |
ES2564358T3 (es) | 2010-10-15 | 2016-03-22 | The Trustees Of Columbia University In The City Of New York | Genes relacionados con la obesidad y sus proteínas y usos de los mismos |
DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
US8680045B2 (en) | 2010-11-01 | 2014-03-25 | Peptimed, Inc. | Compositions of a peptide targeting system for treating cancer |
PT2635299T (pt) | 2010-11-02 | 2019-10-14 | Univ Columbia | Métodos de tratamento de distúrbios de perda de cabelo |
US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
SG190412A1 (en) | 2010-12-06 | 2013-06-28 | Quark Pharmaceuticals Inc | Double stranded oligonucleotide compounds comprising threose modifications |
US9150926B2 (en) | 2010-12-06 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of adrenocortical tumors using human microRNA-483 |
CN103347392B (zh) | 2010-12-22 | 2016-10-12 | 纽约市哥伦比亚大学理事会 | 组蛋白乙酰转移酶调节剂和其用途 |
SG192961A1 (en) | 2011-03-03 | 2013-09-30 | Quark Pharmaceuticals Inc | Compositions and methods for treating lung disease and injury |
TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Hsp47表現調控強化用類視色素脂質體 |
US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
MX2014002535A (es) | 2011-09-02 | 2015-07-17 | Univ Columbia | Inhibidores de camkii, ip3r, calcineurina, p38 y mk2/3 para tratar las alteraciones metabolicas de la obesidad. |
US9352312B2 (en) | 2011-09-23 | 2016-05-31 | Alere Switzerland Gmbh | System and apparatus for reactions |
SG11201401477XA (en) | 2011-10-14 | 2014-07-30 | Genentech Inc | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE |
ES2897565T3 (es) | 2011-10-18 | 2022-03-01 | Dicerna Pharmaceuticals Inc | Lípidos catiónicos de amina y uso de los mismos |
MX356814B (es) | 2011-11-03 | 2018-06-13 | Quark Pharmaceuticals Inc | Métodos y composiciones para neuroprotección. |
JP6212107B2 (ja) | 2012-03-29 | 2017-10-11 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 脱毛障害を処置するための方法 |
UY34752A (es) | 2012-04-20 | 2013-11-29 | Futuragene Israel Ltd | Agentes para el control de la chinche del eucalipto |
US20150082490A1 (en) | 2012-04-23 | 2015-03-19 | Futuragene Israel Ltd. | Glycaspis Brimblecombei Control Agents |
EP2844261B1 (en) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
DK2877494T3 (da) | 2012-07-23 | 2020-09-21 | La Jolla Inst Allergy & Immunology | PTPRS og proteoglycaner i autoimmun sygdom |
CN104903449A (zh) | 2012-10-03 | 2015-09-09 | 富优基尼以色列股份有限公司 | 瘿蜂防治剂 |
ES2776029T3 (es) | 2012-10-08 | 2020-07-28 | St Jude Childrens Res Hospital | Terapias basadas en el control de la estabilidad y función de las células T reguladoras por medio de un eje neuropilina-1:semaforina |
US9920316B2 (en) | 2013-03-14 | 2018-03-20 | Pioneer Hi-Bred International, Inc. | Compositions and methods to control insect pests |
EP2968551B1 (en) | 2013-03-15 | 2021-05-05 | The Trustees of Columbia University in the City of New York | Fusion proteins and methods thereof |
EP2810952A1 (en) | 2013-06-03 | 2014-12-10 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Novel pest control methods |
WO2015002969A1 (en) | 2013-07-03 | 2015-01-08 | City Of Hope | Anticancer combinations |
US10584387B2 (en) | 2013-10-09 | 2020-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Detection of hepatitis delta virus (HDV) for the diagnosis and treatment of Sjögren's syndrome and lymphoma |
WO2015070158A1 (en) | 2013-11-11 | 2015-05-14 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety |
US9682123B2 (en) | 2013-12-20 | 2017-06-20 | The Trustees Of Columbia University In The City Of New York | Methods of treating metabolic disease |
JP6372930B2 (ja) | 2013-12-27 | 2018-08-15 | 国立大学法人高知大学 | 悪性腫瘍の治療薬 |
EP3169309B1 (en) | 2014-07-16 | 2023-05-10 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
WO2016059187A1 (en) * | 2014-10-16 | 2016-04-21 | Universite De Strasbourg | Method of capturing and identifying novel rnas |
AU2015346281B2 (en) | 2014-11-12 | 2021-12-02 | Nmc, Inc. | Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same |
EP3925979A3 (en) | 2014-12-23 | 2022-03-23 | The Trustees of Columbia University in the City of New York | Fgfr-tacc fusion proteins and methods thereof |
US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
WO2016145005A1 (en) | 2015-03-09 | 2016-09-15 | University Of Kentucky Research Foundation | Rna nanoparticles for brain tumor treatment |
US10781446B2 (en) | 2015-03-09 | 2020-09-22 | University Of Kentucky Research Foundation | RNA nanoparticle for treatment of gastric cancer |
WO2016145008A2 (en) | 2015-03-09 | 2016-09-15 | University Of Kentucky Research Foundation | Mirna for treatment of breast cancer |
US11279768B1 (en) | 2015-04-03 | 2022-03-22 | Precision Biologics, Inc. | Anti-cancer antibodies, combination therapies, and uses thereof |
WO2016168784A2 (en) | 2015-04-17 | 2016-10-20 | University Of Kentucky Research Foundation | Rna nanoparticles and method of use thereof |
EP3289104B1 (en) | 2015-04-29 | 2020-11-04 | New York University | Method for treating high-grade gliomas |
JP6980534B2 (ja) | 2015-06-25 | 2021-12-15 | ザ チルドレンズ メディカル センター コーポレーション | 造血幹細胞の増大、富化、および維持に関する方法および組成物 |
US10072065B2 (en) | 2015-08-24 | 2018-09-11 | Mayo Foundation For Medical Education And Research | Peptide-mediated delivery of immunoglobulins across the blood-brain barrier |
EP3702470A3 (en) | 2015-09-09 | 2020-10-07 | The Trustees of Columbia University in the City of New York | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease |
US10857145B2 (en) | 2015-09-29 | 2020-12-08 | Duke University | Compositions and methods for identifying and treating dystonia disorders |
UA123773C2 (uk) | 2015-10-30 | 2021-06-02 | Дженентек, Інк. | ВИДІЛЕНЕ АНТИТІЛО ПРОТИ HtrA1 ТА ЙОГО ЗАСТОСУВАННЯ ПРИ ЛІКУВАННІ ПОВ'ЯЗАНОГО З HtrA1 ПОРУШЕННЯ АБО ХВОРОБИ ОКА |
KR102740699B1 (ko) | 2015-12-13 | 2024-12-09 | 닛토덴코 가부시키가이샤 | 높은 활성 및 감소한 오프 타겟을 위한 sirna 구조 |
US11072777B2 (en) | 2016-03-04 | 2021-07-27 | University Of Louisville Research Foundation, Inc. | Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs) |
US20190119642A1 (en) | 2016-03-15 | 2019-04-25 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
US10883108B2 (en) | 2016-03-31 | 2021-01-05 | The Schepens Eye Research Institute, Inc. | Endomucin inhibitor as an anti-angiogenic agent |
WO2018057575A1 (en) | 2016-09-21 | 2018-03-29 | Alnylam Pharmaceuticals, Inc | Myostatin irna compositions and methods of use thereof |
CN107858405B (zh) * | 2017-10-12 | 2021-09-24 | 华南农业大学 | 一种测定外源dsRNA对瓢虫毒性影响的方法 |
WO2019199673A1 (en) | 2018-04-09 | 2019-10-17 | President And Fellows Of Harvard College | Modulating nuclear receptors and methods of using same |
CN109266677B (zh) * | 2018-08-31 | 2021-11-23 | 中国烟草总公司郑州烟草研究院 | 一种全长转录因子酵母双杂交文库的构建方法 |
CN109183158B (zh) * | 2018-08-31 | 2021-11-23 | 中国烟草总公司郑州烟草研究院 | 一种全长转录因子酵母单杂交文库的构建方法 |
JP2022501388A (ja) | 2018-09-19 | 2022-01-06 | ラホヤ インスティチュート フォー イミュノロジー | 関節リウマチにおけるptprs及びプロテオグリカン |
PT3880212T (pt) | 2018-11-16 | 2024-02-08 | Nitto Denko Corp | Formulação e métodos de administração de rna de interferência para tumores malignos |
US20220091135A1 (en) * | 2019-01-04 | 2022-03-24 | Kyoto University | Test method for ulcerative colitis and primary sclerosing cholangitis |
US12215382B2 (en) | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
CN110229839B (zh) * | 2019-06-04 | 2021-06-08 | 中国农业大学 | 一种提升大肠杆菌dsRNA表达产率的方法 |
CN110746497A (zh) * | 2019-11-18 | 2020-02-04 | 维塔恩(广州)医药有限公司 | 肺炎衣原体相关抗原短肽及其应用 |
CN110804088A (zh) * | 2019-11-18 | 2020-02-18 | 维塔恩(广州)医药有限公司 | 巨细胞病毒相关抗原短肽及其应用 |
EP3825408A1 (en) | 2019-11-19 | 2021-05-26 | FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. | Methods of multi-species insect pest control |
CR20220278A (es) | 2019-12-18 | 2022-07-01 | Novartis Ag | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos |
CN115176005A (zh) | 2019-12-18 | 2022-10-11 | 诺华股份有限公司 | 用于治疗血红蛋白病的组合物和方法 |
BR112022013589A2 (pt) | 2020-01-08 | 2022-09-13 | Regeneron Pharma | Tratamento da fibrodisplasia ossificante progressiva |
WO2021150300A1 (en) | 2020-01-22 | 2021-07-29 | Massachusetts Institute Of Technology | Inducible tissue constructs and uses thereof |
WO2021173965A1 (en) | 2020-02-28 | 2021-09-02 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
CN113638055B (zh) * | 2020-05-22 | 2023-07-07 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种制备双链rna测序文库的方法 |
WO2022147480A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Oncolytic virus encoding sialidase and multispecific immune cell engager |
WO2022269518A2 (en) | 2021-06-23 | 2022-12-29 | Novartis Ag | Compositions and methods for the treatment of hemoglobinopathies |
EP4381069A1 (en) | 2021-08-02 | 2024-06-12 | Universite De Montpellier | Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22 |
CN113533007B (zh) * | 2021-08-06 | 2023-11-24 | 青岛瑞斯凯尔生物科技有限公司 | 一种抗体染色标记装置及其方法 |
PE20241173A1 (es) | 2021-10-14 | 2024-05-28 | Arsenal Biosciences Inc | Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica |
TW202417626A (zh) | 2022-09-13 | 2024-05-01 | 美商亞森諾生物科學公司 | 具有共表現的tgfbr shrna之免疫細胞 |
WO2024059824A2 (en) | 2022-09-16 | 2024-03-21 | Arsenal Biosciences, Inc. | Immune cells with combination gene perturbations |
WO2024186656A1 (en) | 2023-03-03 | 2024-09-12 | Arsenal Biosciences, Inc. | Systems targeting psma and ca9 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US589801A (en) * | 1897-09-07 | woltereck | ||
EP1213348A2 (en) | 1985-03-21 | 2002-06-12 | Johnston, Stephen, Ph.D. | Parasite-derived resistance |
US6608241B1 (en) | 1985-10-29 | 2003-08-19 | Monsanto Technology Llc | Protection of plants against viral infection |
IL81737A (en) | 1986-03-28 | 1992-11-15 | Calgene Inc | Regulation of gene expression in plant cells |
US5017488A (en) * | 1986-04-01 | 1991-05-21 | University Of Medicine And Dentistry Of New Jersey | Highly efficient dual T7/T3 promoter vector PJKF16 and dual SP6/T3 promoter vector PJFK15 |
US4970168A (en) * | 1989-01-27 | 1990-11-13 | Monsanto Company | Virus-resistant plants |
JPH04507083A (ja) * | 1989-05-19 | 1992-12-10 | ヘム・リサーチ・インコーポレーテッド | 規定された構造の短い治療用dsRNA |
HUT57265A (en) | 1989-11-03 | 1991-11-28 | Zaadunie Bv | Process for producing plants of diminished infection-sensitivity |
US5837848A (en) * | 1990-03-16 | 1998-11-17 | Zeneca Limited | Root-specific promoter |
EP0524254A4 (en) * | 1990-03-30 | 1993-04-28 | The President And Fellows Of Harvard College | A binary genetic system to control expression of a transgene in a transgenic animal |
US5831011A (en) * | 1990-07-27 | 1998-11-03 | Mycogen Corporation | Bacillus thuringiensis genes encoding nematode-active toxins |
US5459252A (en) * | 1991-01-31 | 1995-10-17 | North Carolina State University | Root specific gene promoter |
EP0631629B1 (en) | 1992-03-20 | 2003-12-03 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Fungus-responsive chimaeric gene |
DE4234131C2 (de) * | 1992-10-09 | 1995-08-24 | Max Planck Gesellschaft | Transgener pathogen-resistenter Organismus |
CA2088379A1 (en) * | 1993-01-29 | 1994-07-30 | University Of British Columbia | Biological systems incorporating stress-inducible genes and reporter constructs for environmental biomonitoring and toxicology |
IL104830A (en) * | 1993-02-23 | 2001-01-28 | Yissum Res Dev Co | A chimeric plasmid containing a non-structural gene for the protease of the potato virus and its various uses |
DE4317845A1 (de) | 1993-05-28 | 1994-12-01 | Bayer Ag | Desoxyribonukleinsäuren |
US6214544B1 (en) * | 1994-06-15 | 2001-04-10 | The Trustees Of Columbia University | Method to identify tumor suppressor genes |
US5691140A (en) * | 1995-05-18 | 1997-11-25 | New England Biolabs, Inc. | Bidirectional in vitro transcription vectors utilizing a single RNA polymerase for both directions |
GB9510944D0 (en) * | 1995-05-31 | 1995-07-26 | Bogaert Thierry | Assays and processes for the identification of compounds which control cell behaviour,the compounds identified and their use in the control of cell behaviour |
DK0832207T3 (da) * | 1995-06-02 | 2000-11-06 | M & E Biotech As | Fremgangsmåde til identifikation af biologisk aktive peptider og nukleinsyrer |
US5679551A (en) * | 1995-10-31 | 1997-10-21 | Board Of Regents, The University Of Texas System | Unique double-stranded RNAS associated with the Trichomonas vaginalis virus |
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
DE19631919C2 (de) * | 1996-08-07 | 1998-07-16 | Deutsches Krebsforsch | Anti-Sinn-RNA mit Sekundärstruktur |
JP4339404B2 (ja) * | 1996-08-09 | 2009-10-07 | ケイヘーネ・エヌ・ブイ | 線虫及び/又はアリマキに対する耐性 |
PL332311A1 (en) * | 1996-09-18 | 1999-08-30 | Christian Jung | Immunity gene against nematodes |
AU4470697A (en) | 1996-10-03 | 1998-04-24 | Hajime Kato | Method for hydrocarbon steam reforming |
EA199900535A1 (ru) | 1996-12-18 | 2000-02-28 | Эксон Кемикэл Пейтентс Инк. | Смеси полимеров, которым придана совместимость, приготовленные с использованием полифункционального агента |
GB9703146D0 (en) | 1997-02-14 | 1997-04-02 | Innes John Centre Innov Ltd | Methods and means for gene silencing in transgenic plants |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
EP1068311B2 (en) * | 1998-04-08 | 2020-12-09 | Commonwealth Scientific and Industrial Research Organisation | Methods and means for obtaining modified phenotypes |
AR020078A1 (es) * | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
GB9814536D0 (en) | 1998-07-03 | 1998-09-02 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
AUPR621501A0 (en) | 2001-07-06 | 2001-08-02 | Commonwealth Scientific And Industrial Research Organisation | Delivery of ds rna |
AP2008004416A0 (en) | 2005-09-16 | 2008-04-30 | Monsanto Technology Llc | Methods for genetic control of insect infestationsin plants and compositions thereof |
-
1998
- 1998-12-09 GB GBGB9827152.1A patent/GB9827152D0/en not_active Ceased
-
1999
- 1999-07-02 AT AT04011161T patent/ATE433500T1/de active
- 1999-07-02 DE DE29924299U patent/DE29924299U1/de not_active Expired - Lifetime
- 1999-07-02 EP EP01129274.5A patent/EP1197567B2/en not_active Expired - Lifetime
- 1999-07-02 EP EP10182431A patent/EP2374901A1/en not_active Withdrawn
- 1999-07-02 EP EP08022353A patent/EP2045336A3/en not_active Withdrawn
- 1999-07-02 PL PL384205A patent/PL213379B1/pl unknown
- 1999-07-02 MX MXPA00012955 patent/MX234065B/es not_active IP Right Cessation
- 1999-07-02 NZ NZ509182A patent/NZ509182A/en not_active IP Right Cessation
- 1999-07-02 EP EP04011161A patent/EP1484415B1/en not_active Revoked
- 1999-07-02 EP EP99932836A patent/EP1093526A2/en not_active Withdrawn
- 1999-07-02 DK DK01129274.5T patent/DK1197567T4/en active
- 1999-07-02 AT AT01129274T patent/ATE419383T1/de active
- 1999-07-02 GB GB0020485A patent/GB2349885B/en not_active Expired - Fee Related
- 1999-07-02 KR KR20047010184A patent/KR20040066200A/ko active Search and Examination
- 1999-07-02 ES ES04011161T patent/ES2327334T3/es not_active Expired - Lifetime
- 1999-07-02 BR BR9911802-5A patent/BR9911802A/pt active Search and Examination
- 1999-07-02 IL IL14046799A patent/IL140467A0/xx active IP Right Grant
- 1999-07-02 JP JP2000558236A patent/JP4353639B2/ja not_active Expired - Fee Related
- 1999-07-02 PT PT04011161T patent/PT1484415E/pt unknown
- 1999-07-02 DE DE69940219T patent/DE69940219D1/de not_active Expired - Lifetime
- 1999-07-02 DK DK04011161T patent/DK1484415T3/da active
- 1999-07-02 PL PL347978A patent/PL201425B1/pl unknown
- 1999-07-02 DE DE69940984T patent/DE69940984D1/de not_active Expired - Lifetime
- 1999-07-02 CZ CZ20010014A patent/CZ303494B6/cs not_active IP Right Cessation
- 1999-07-02 CN CNB998101966A patent/CN1198938C/zh not_active Expired - Fee Related
- 1999-07-02 CA CA2332619A patent/CA2332619C/en not_active Expired - Fee Related
- 1999-07-02 DE DE1093526T patent/DE1093526T1/de active Pending
- 1999-07-02 KR KR1020077005038A patent/KR20070041607A/ko active Search and Examination
- 1999-07-02 CN CN200510052742XA patent/CN1657620A/zh active Pending
- 1999-07-02 DE DE29924298U patent/DE29924298U1/de not_active Expired - Lifetime
- 1999-07-02 WO PCT/EP1999/004718 patent/WO2000001846A2/en active Application Filing
- 1999-07-02 ES ES01129274.5T patent/ES2320527T5/es not_active Expired - Lifetime
- 1999-07-02 CN CNA2006100944808A patent/CN1900319A/zh active Pending
- 1999-07-02 GB GB0206600A patent/GB2370275B/en not_active Expired - Fee Related
- 1999-07-02 HK HK00107819A patent/HK1029142A1/xx not_active IP Right Cessation
- 1999-07-02 PL PL390495A patent/PL216779B1/pl unknown
- 1999-07-02 CZ CZ2012-309A patent/CZ304897B6/cs not_active IP Right Cessation
- 1999-07-02 PT PT01129274T patent/PT1197567E/pt unknown
- 1999-07-02 CA CA2789083A patent/CA2789083C/en not_active Expired - Fee Related
- 1999-07-02 HU HU0103571A patent/HU230602B1/hu not_active IP Right Cessation
- 1999-07-02 AU AU49079/99A patent/AU769223B2/en not_active Ceased
- 1999-07-02 RU RU2000133315/13A patent/RU2240349C2/ru not_active IP Right Cessation
- 1999-07-02 KR KR1020017000068A patent/KR100563295B1/ko not_active IP Right Cessation
- 1999-07-02 GB GB0118514A patent/GB2362885B/en not_active Expired - Fee Related
- 1999-07-02 KR KR1020067011420A patent/KR20060071438A/ko active Search and Examination
-
2000
- 2000-12-19 ZA ZA200007653A patent/ZA200007653B/en unknown
- 2000-12-21 IL IL140467A patent/IL140467A/en not_active IP Right Cessation
-
2001
- 2001-01-02 NO NO20010019A patent/NO327729B1/no not_active IP Right Cessation
- 2001-01-02 IS IS5802A patent/IS2816B/is unknown
- 2001-01-02 IN IN6DE2001 patent/IN2001DE00006A/en unknown
-
2002
- 2002-01-25 US US10/057,108 patent/US20030061626A1/en not_active Abandoned
-
2003
- 2003-12-17 US US10/738,886 patent/US20040133943A1/en not_active Abandoned
-
2004
- 2004-04-16 US US10/826,522 patent/US8114980B2/en not_active Expired - Fee Related
-
2006
- 2006-06-20 IN IN3568DE2006 patent/IN2006DE03568A/en unknown
-
2007
- 2007-03-06 IL IL181727A patent/IL181727A/en not_active IP Right Cessation
-
2009
- 2009-01-07 JP JP2009001591A patent/JP2009112311A/ja active Pending
- 2009-03-23 CY CY20091100345T patent/CY1108920T1/el unknown
- 2009-08-31 CY CY20091100907T patent/CY1109324T1/el unknown
-
2013
- 2013-09-09 JP JP2013186110A patent/JP5847776B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1197567B1 (en) | Characterisation of gene function using double stranded RNA inhibition | |
Lozano et al. | Efficient gene targeting and removal of foreign DNA by homologous recombination in the picoeukaryote Ostreococcus | |
US7005423B1 (en) | Characterization of gene function using double stranded RNA inhibition | |
AU2004200852B2 (en) | Characterisation of gene function using double stranded RNA inhibition | |
WO2006056615A1 (en) | Enhancer-containing gene trap vectors for random and targeted gene trapping | |
El Mouridi et al. | Targeted and random transposon-assisted single-copy transgene insertion in C. elegans | |
Dinneen et al. | Universal Single Copy Knock-In System in Caenorhabditis elegans: One Plasmid to Target All Chromosomes | |
Deka | Gene Cloning | |
McEachern | INTER-KINGDOM EPIGENETICS: CHARACTERIZATION OF MAIZE B1 TANDEM |